STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
With a new deal announced this week, the relationship between Eli Lilly and a telehealth company that markets GLP-1s is expected to grow more complicated.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.